Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes
- PMID: 15790789
- DOI: 10.1182/blood-2004-09-3663
Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes
Abstract
Tumor antigen-specific CD4+ and CD8+ T lymphocytes, especially interferon-gamma (IFN-gamma)-producing type-1 helper T (Th1) and type-1 cytotoxic T (Tc1) cells, play a crucial role in tumor eradication. Adoptive transfer using tumor-specific Th1 and Tc1 cells is a promising therapeutic strategy for tumor immunotherapy. However, its clinical application has been hampered because of difficulties in generating tumor-specific Th1 cells from patients with tumors. To overcome this problem, we have developed an efficient method to prepare tumor-specific Th1 and Tc1 cells. T-cell receptor (TCR) alpha and beta genes obtained from an HLA-A24-restricted, Wilms tumor 1 (WT1) peptide-specific Tc clone were lentivirally transduced to polyclonally activated Th1 and Tc1 cells. As expected, TCR gene-modified Tc1 cells showed cytotoxicity and IFN-gamma production in response to peptide-loaded lymphoblastoid cell lines, WT1 gene-transduced cells, and freshly isolated leukemia cells expressing both WT1 and HLA-A24. Surprisingly, we further demonstrated that Th1 cells transduced with HLA-class I-restricted TCR genes also showed both cytotoxicity and cytokine production in an HLA-A24-restricted manner. In contrast to gene-modified Tc1 cells, Th1 cells produced high amounts of interleukin-2 (IL-2) in addition to IFN-gamma, which is beneficial for induction of antitumor cellular immunity. Thus, TCR gene-modified HLA-class I-restricted Th1 and Tc1 cells are a powerful strategy for the application to adoptive immunotherapy of human cancer.
Similar articles
-
HLA-DPB1*05: 01-restricted WT1332-specific TCR-transduced CD4+ T lymphocytes display a helper activity for WT1-specific CTL induction and a cytotoxicity against leukemia cells.J Immunother. 2013 Apr;36(3):159-70. doi: 10.1097/CJI.0b013e3182873581. J Immunother. 2013. PMID: 23502763
-
Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor.Cancer Res. 2004 Feb 15;64(4):1490-5. doi: 10.1158/0008-5472.can-03-2780. Cancer Res. 2004. PMID: 14973062
-
Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells.Cancer Sci. 2006 Sep;97(9):920-7. doi: 10.1111/j.1349-7006.2006.00271.x. Epub 2006 Jul 13. Cancer Sci. 2006. PMID: 16856879 Free PMC article.
-
Immunotherapy for leukemia targeting the Wilms' tumor gene.Leuk Lymphoma. 2001 Jul;42(3):267-73. doi: 10.3109/10428190109064583. Leuk Lymphoma. 2001. PMID: 11699391 Review.
-
WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells.Blood Cells Mol Dis. 2008 Jan-Feb;40(1):113-6. doi: 10.1016/j.bcmd.2007.06.018. Epub 2007 Sep 12. Blood Cells Mol Dis. 2008. PMID: 17855129 Review.
Cited by
-
Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential.Front Oncol. 2021 Feb 16;10:593848. doi: 10.3389/fonc.2020.593848. eCollection 2020. Front Oncol. 2021. PMID: 33680923 Free PMC article. Review.
-
Lentiviral vectors encoding human MUC1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene: potential for universal and safe cancer immunotherapy.Cancer Immunol Immunother. 2009 Jun;58(6):977-87. doi: 10.1007/s00262-008-0624-0. Epub 2008 Nov 21. Cancer Immunol Immunother. 2009. PMID: 19023569 Free PMC article.
-
T cell receptor gene therapy for cancer.Hum Gene Ther. 2009 Nov;20(11):1240-8. doi: 10.1089/hum.2009.146. Hum Gene Ther. 2009. PMID: 19702439 Free PMC article. Review.
-
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.Biol Blood Marrow Transplant. 2010 Aug;16(8):1037-69. doi: 10.1016/j.bbmt.2010.05.005. Epub 2010 May 24. Biol Blood Marrow Transplant. 2010. PMID: 20580849 Free PMC article. Review.
-
Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy.Pharmaceutics. 2023 Jan 30;15(2):452. doi: 10.3390/pharmaceutics15020452. Pharmaceutics. 2023. PMID: 36839774 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials